Invitae Completes $120 Million Series F Financing
October 13, 2014

SAN FRANCISCO, October 13, 2014 – Invitae Corporation, a genetic information company, today announced the completion of a $120 million Series F financing. Invitae plans to use the proceeds to accelerate the build out of its infrastructure for its genetic information business, as well as to expand its global presence.

New investors participating in the round included (in alphabetical order) The Broe Group, Decheng Capital, Deerfield Management LLC, OrbiMed, Perceptive Advisors, Rock Springs Capital and Wellington Management Company, LLP, among others. Existing investors participating in the financing included Casdin Capital, Genesys Capital, Genomic Health, Inc. (NASDAQ: GHDX), Randy Scott, Redmile Group and Thomas McNerney & Partners, among others. J.P. Morgan Securities LLC acted as sole placement agent on the financing.

About Invitae Corporation

Invitae, based in San Francisco, is a genetic information company whose mission is to bring genetic information into routine medical practice to improve the quality of healthcare. Specializing in genetic diagnostics for hereditary disorders, Invitae’s goal is to aggregate the world’s genetic tests into a single service with better quality, faster turnaround time, and a lower price than many single-gene diagnostic tests today. The company currently provides a single diagnostic test comprising over 200 genes for a variety of genetic disorders associated with cancer, cardiology, neurology and pediatrics. Invitae has raised a total of $207 million from investors to date.

Copyright ? 2011 Decheng Capital LLC. All Rights Reserved.
浙江20选5预测推荐 陕西快乐十分开奖助手 中彩票信息 河内五分彩对刷流水稳赢 og视讯最新 河内五分彩走势图彩经网 下载湖北11选5彩票通 极速快乐十分遗漏 在线棋牌怎么提款 安徽时时彩规则介绍一首页 查看湖北30选5走势图 什么情况下ag会追杀你 香港六合彩79开奖结果 极速飞艇平台 山西快乐十分86期开奖 bet365体育投注怎么玩 闲来麻将湖南麻将下载